ABO Histo-Blood Groups Influence Makeup of Gut Microbiome
|
By LabMedica International staff writers Posted on 01 Feb 2021 |

Image: False-colored electron microscopic image of Bifidobacterium that are one of the major genera of bacteria that make up the gastrointestinal tract and are associated with variants in the lactase gene locus (Photo courtesy of The Keck Science Department of the Claremont Colleges)
Recent genome-wide association studies yielded inconsistent, underpowered and rarely replicated results such that the role of human host genetics as a contributing factor to microbiome assembly and structure remains uncertain.
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
Latest Molecular Diagnostics News
- RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
- Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
- New AI Tool Improves Detection of Genetic Causes in Rare Disorders
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
- Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers
- New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
- First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
- Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
- New Respiratory Panel Expands Pathogen Detection to 25 Targets
- Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
- Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
- Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
- Blood Test Helps Guide Treatment in Older Women with Breast Cancer
- Rapid Host-Response Test Distinguishes Bacterial and Viral Infections in Minutes
- Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
- Study Reveals Widespread Errors in Gene Variant Naming
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








